Author: admin

At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses the need for clinical trials in non-clear cell renal cell carcinoma (RCC) and new research in papillary RCC (pRCC). Emerging trials in the non-clear cell RCC subtype, pRCC, are hoped to improve the availability of therapies specifically approved for this disease.

At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (The University of Texas MD Anderson Cancer Center, TX) discusses papillary renal cell carcinoma (pRCC) and prospective immunotherapy. pRCC is a relatively uncommon subtype of renal cell carcinoma (RCC) that is distinct from the more common clear cell RCC subtype. It is possible that progress in immunotherapeutic research in clear cell RCC that target common components of the immune system may be clinically applicable for patients with pRCC.

At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses recent developments in the research of kidney cancer management. Identification of cancer subtypes through molecular profiling may guide future trial design and management options. Combination therapies have the potential to improve efficacy. There are a variety of online resources for patients interested in participating in clinical trials.

At the Thirteenth International Kidney Cancer Symposium, Dr Laurence Albiges (Gustave Roussy, France) provides an overview of papillary renal cell carcinoma (pRCC) and management options for these patients. pRCC comprises 1015% of renal cell carcinoma and specific therapies are not available. There are two clinically distinct types of pRCC. The more common Type 1 pRCC is associated with a mutation in the MET gene.

At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC). pRCC is the second most common subtype of renal cell carcinoma and is associated with poor clinical outcomes. Dr Choueiri describes how molecular approaches help direct current research in this field and how inappropriate c-Met activation in cancer cells may be important in pRCC progression. Volitinib is a novel c-Met inhibitor; this Phase 2 trial is an open-label, global and multicentre…

At the Thirteenth International Kidney Cancer Symposium, Prof David Kwiatkowski (Brigham and Women’s Hospital, MA) discusses targeting the mTOR pathway in kidney cancer treatment. It may be clinically necessary to target different proteins, mTOR, TSC1 and TSC2, of the mTOR pathway. Mutations in genes encoding for these proteins correlate with therapeutic response, and this may influence clinical trial design and provide the basis for personalised medicine in kidney cancer.

At the Thirteenth International Kidney Cancer Symposium, Dr James Hsieh (Memorial Sloan-Kettering Cancer Center, NY) discusses chromophobe renal cell carcinoma (RCC), which comprises 5% of RCC. Chromophobe RCC variants are important determinants in current treatment options. The incidence of incurable, metastatic disease in chromophobe RCC is 5%. Recent studies have improved the molecular understanding of chromophobe RCC and are hoped to direct therapeutic development.

At the Thirteenth International Kidney Cancer Symposium, Dr JianJun Gao (University of Texas MD Anderson Cancer Center, TX) provides an overview of renal medullary carcinoma (RMC). RMC is a rare and aggressive renal cell carcinoma subtype that primarily occurs in African-American patients with sickle cell trait. Although research in RMC has remained in the preclinical stage, it is hoped that significant progress in more common kidney cancer subtypes will provide applicable data that will improve the management of patients with RMC.

At the Thirteenth International Kidney Cancer Symposium, Dr Hans Hammers (Johns Hopkins, MD) encourages kidney cancer patients to take an active role in health care. Currently, a strategic and patient-tailored approach is recommended in kidney cancer management. Dr Hammers discusses how clinical trials represent opportunities for patients to access new medicines and further therapy development.

At the Thirteenth International Kidney Cancer Symposium, Dr Hans Hammers (Johns Hopkins, MD) discusses the Phase 1 clinical trial that studied the immune checkpoint inhibitors, nivolumab and ipilimumab, in metastatic renal cell carcinoma (mRCC). The primary endpoint was to access safety and tolerability, and the secondary endpoint was to access efficacy. Overall, side effects were manageable and objective response was greater than previously reported with nivolumab monotherapy. These findings directed a subsequent Phase 3 trial.

At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses highlights from the Thirteenth International Kidney Cancer Symposium. This meeting provides a forum for a varied audience with an interest in renal cell carcionoma (RCC) to exchange information that will help direct future research. The new immunotherapies that target the immune basis of cancer may have clinical applicability in both clear cell and non-clear cell RCC. It is also important to target the unique components of the RCC subtypes. Patients are encouraged to learn about clinical trials and participate if appropriate.

At the Thirteenth International Kidney Cancer Symposium, Dr Elizabeth Plimack (Fox Chase Cancer Center, PA) discusses prospective immunotherapy in kidney cancer management. Newer immunotherapeutic agents have demonstrated efficacy and are expected to be approved for kidney cancer soon. Collaborations between different drug manufactures have facilitated progress in combination therapies.

At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses his research on stool microbiome. Although in preliminary stages, research in kidney cancer patients suggests that protective bacterial species of the stool microbiome may protect against cancer therapy-induced diarrhoea.

At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) provides an overview on current strategies in kidney cancer management. Focus in this field is moving away from VEGF and mTOR inhibitors. Current topics of interest include novel targets, acquired mechanisms of therapy resistance and immune checkpoint inhibitors. In lieu of biomarker availability for predicting therapy response, genetic sequencing methods are used to guide research in new combination therapies.

At the Thirteenth International Kidney Cancer Symposium, Dr Abraham Ari Hakimi (Memorial Sloan-Kettering Cancer Center, NY) discusses the current understanding of sarcomatoid renal cell carcinoma (RCC). Sarcomatoid RCC is an aggressive subtype of RCC and presents significant clinical challenges. Modern technologies, including whole-genome sequencing, are hoped to improve the understanding of this disease biology, which ultimately guides treatment and improves disease management.

At the Thirteenth International Kidney Cancer Symposium, Carolyn Konosky (Kidney Cancer Association, IL) encourages kidney cancer patients to have an active role in health care. The Kidney Cancer Association website offers a variety of resources for patients.         thirteenth international kidney cancer symposium, international kidney cancer symposium, kidney cancer patients to have an active role,

At the Thirteenth International Kidney Cancer Symposium, Carolyn Konosky (Kidney Cancer Association, IL) provides an overview of the Kidney Cancer Association, which aims to progress and disseminate understanding of kidney cancer. These meetings provide a forum for different audiences with an interest in kidney cancer to exchange information that contributes to future research.

Latest Lung Cancer Updates from ESMO 2014 – Chemotherapy Advances by Dr. Sunil Verma

Latest Lung Cancer Updates from ESMO 2014 – Advances in ALK Positive NSCLC by Dr. Sunil Verma

Dr. James Brugarolas, M.D., Ph.D. Kidney Cancer Program Leader Associate Professor of Internal Medicine & Developmental Biology University of Texas Southwestern Medical Center discusses RCC Classification at the Kidney Cancer meeting in Chicago

Bernard J. Escudier, M.D. accepts the 2014 Eugene P. Schonfeld Award at the Kidney Cancer meeting in Chicago

Dr. Hiral D. Parekh, M.D. discusses Cost Analysis of an Initial Observation Approach in Metastatic Renal Cell Carcinoma at the Kidney Cancer meeting in Chicago

Dr. Laurence Albiges, M.D., Ph.D. discusses Differential expression of c-MET between primary and metastatic sites in clear cell Renal Cell Carcinomas (ccRCCs) at the Kidney Cancer meeting in Chicago.

Dr. Andre P. Fay, M.D. discusses Whole-Exome Sequencing Predicting Two Extreme Phenotypes of Response to VEGF-targeted Therapies in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mRCC) at the Kidney Cancer meeting in Chicago

Dr. Joshua Lang, M.D., M.S. discusses Development of Pharmacodynamic Biomarkers in Circulating Renal Cancer Cells at the Kidney Cancer meeting in Chicago

Dr. Andrew G. Winer discusses Tumor Purity and Immune Cell Infiltration as a Prognostic Risk Predictor for Clear Cell Renal Cell Carcinoma (ccRCC)

Dr. David Kwiatkowski talks about The mTOR signaling pathwayWho responds to rapalogs and why? at the Kidney Cancer meeting in Chicago.

Dr. Harriet Kluger, M.D.Associate Professor Yale Cancer Center discusses The Met Pathway as a Target in RCC at the Kidney Cancer meeting in Chicago

Dr. David F. McDermott discusses Immune correlates and long-term follow-up of a Phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC) at the Kidney Cancer meeting in Chicago

Dr. Thai Ho, M.D., Ph.D.Mayo Clinic Arizona discusses The Evolving Role of Chromatin and Epigenetics in RCC at the Kidney Cancer meeting in Chicago

Dr. Toni K. Choueiri discusses Risk Factors and a Model to Predict Toxicity-related Treatment Discontinuation in Patients with Metastatic Renal Cell Carcinoma (mRCC) Treated with Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy: Results from the International Metastatic RCC Database Consortium (IMDC)

Dr. Sumanta K. Pal, MD;1 Min Li, PhD;2 Xiwei Wu, PhD;3 Paul Frankel, PhD2   1Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA; 2Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA; 3Department of Molecular & Cell Biology, City of Hope Comprehensive Cancer Center, Duarte, CA discusses Bacteriomic profiling reveals potential etiology for vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI)-related diarrhea in patients with metastatic renal cell carcinoma (mRCC) at the Kidney Cancer meeting in Chicago

Dr. Georg A. BjarnasonDivision of Medical OncologySunnybrook Odette Cancer CentreAssociate Professor, Faculty of Medicine, University of Toronto discusses Dose Reduction or Treatment Interruption Pro: Treatment Interruption and individualized dose/schedule alterationIndividualized Sunitinib as an example? at the Kidney Cancer meeting in Chicago

Dr. David I. Quinn MBBS (Hons) PhD FRACP FACP Associate Professor of Medicine Chief, Section of GU Medical Oncology Division of Medical Oncology Medical Director, Norris Cancer Hospital & Clinics Co-Leader, Developmental Therapeutics Program Member, USC Institute of Urology Kenneth J. Norris Comprehensive Cancer Center Keck School of Medicine University of Southern California discusses Dose Reduction or TreatmentInterruption: Pro Dose Reduction at the Kidney Cancer meeting in Chicago

Dr. Frede Donskov, M.D., PhD Chair, Danish Renal Cancer Group, DARENCA Aarhus University Hospital Denmark discusses Toxicity as a Biomarker at the Kidney Cancer meeting in Chiacgo

Suzanne L. Topalian of Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center discusses Biomarkers for PD-1 checkpoint inhibition at the Kidney Cancer meeting in Chicago

Dr. Drew Pardoll of Johns Hopkins discusses Basic Concepts and Future Horizons in Cancer Immunotherapy at the Kidney Cancer Meeting in Chiacgo

Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Department of Hematology/Oncology discusses Combination immunotherapy + VEGF targeted therapy is the optimal systemic strategy for metastatic RCC at the Kidney Cancer Meeting in Chiacgo

M. Dror Michaelson, MD PhD MGH Cancer CenterBoston, MA discusses how TKIs are the Optimal Front-Line mRCC Treatment

Dr. Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center discusses the Optimal Front-Line Treatment for mRCC

Toni K. Choueiri, MD Clinical Director and Kidney Cancer Center Director The Lank Center for Genitourinary Oncology Dana-Farber Cancer Institute Brigham and Womens Hospital presents Clinical Trials in non-clear cell RCC: ESPN, ASPEN and beyond at the Kidney Cancer Association meeting in Chicago 2014

Ari Hakimi MD Assistant Professor Urologic Oncology Affiliate Department of Computational Biology MSKCC presents Genomic Characterization of Sarcomatoid Clear Cell RCC at the Kidney Cancer Association meeting in Chicago 2014

Jianjun Gao, MD, PhD Department of Genitourinary Oncology MD Anderson Cancer Center presents Molecular Characterization of Renal Medullary Carcinoma at the Kidney Cancer Association meeting in Chicago 2014

Gabriel G. Malouf, MD, PhD Assistant professor Department of medical oncology Pitié-Salpêtrière Hospital, Paris, France discusses Translocation Renal Cell Carcinomas: Molecular insights and Future Directions at the Kidney Cancer Association meeting in Chiacgo 2014

Laurence Albiges, MD, PhD Lank Center for Genitourinary Oncology presents Papillary Renal Cell Carcinoma at the Kidney Cancer Association meeting in Chicago 2014

James Hsieh MD PhD MSKCC Translational Kidney Cancer Research Program (TKCRP) presents13thIKCS Chicago Rare Kidney Cancer:Chromophobe RCC at the Kidney Cancer Association meeting in Chicago 2014

Michael L. Blute Sr. MD Chief Urology MGH Walter S. Kerr Jr. Professor of Surgery Harvard Medical School presents Case Presentations Kidney Cancer Association meeting in Chicago 2014

Michael L. Blute Jr of MD Anderson presents the Recurrence After Surgery in Non-metastatic RCC with Thrombus; Risk Factors From A Contemporary Multicenter Analysis at the Kidney Cancer Association meeting in Chicago 2014

Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology discusses Cytoreductive Nephrectomy at the Kidney Cancer Association meeting in Chicago 2014

Sarah P. Psutka MD Fellow in Urologic Oncology Mayo Clinic, Rochester, MN presents the Latest On IVC Tumor Thrombus at the Kidney Cancer Association meeting in Chicago 2014